Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "immunology"

157 News Found

GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
News | November 01, 2024

GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus


Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline
News | April 17, 2023

Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline

Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology


Dupixent is a star in Sanofi’s immunology strategy
Biotech | March 29, 2022

Dupixent is a star in Sanofi’s immunology strategy

Dupixent peak sales ambition raised to more than €13 billion


AbbVie begins construction of $70 million biologics manufacturing site in US
News | October 01, 2025

AbbVie begins construction of $70 million biologics manufacturing site in US

The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology


Pfizer agrees to slash prescription drug prices for Americans
News | October 01, 2025

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%


Lilly opens biotech in San Diego
Startup | September 29, 2025

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines


Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
News | September 24, 2025

Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas

The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines


AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
News | September 23, 2025

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent


Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Digitisation | September 11, 2025

Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines